<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558571</url>
  </required_header>
  <id_info>
    <org_study_id>1245.4</org_study_id>
    <secondary_id>EudraCT No 2007-002685-36</secondary_id>
    <nct_id>NCT00558571</nct_id>
  </id_info>
  <brief_title>4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary objective: safety and tolerability of BI 10773 in male and female patients with type
      2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Drug Related Adverse Events</measure>
    <time_frame>from drug administration up to 6 weeks</time_frame>
    <description>number of subjects with investigator-defined drug-related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</measure>
    <time_frame>from drug administration up to 6 weeks</time_frame>
    <description>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Empagliflozin</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 hours(h) after drug administration on day 1 and 28</time_frame>
    <description>maximum concentration of the analyte in plasma after first dose (Cmax, Day 1 ) and at steady state over a uniform dosing interval (Cmax,ss, Day 28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Empagliflozin</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
    <description>time from last dosing to maximum concentration of the analyte in plasma after first dose (Day 1), denoted by tmax; and at steady state (Day 28), denoted by tmax,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Empagliflozin</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
    <description>terminal half-life of the analyte in plasma after first dose (Day 1), denoted by t1/2; and at steady state (Day 28), denoted by t1/2,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of Empagliflozin</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) and over a uniform dosing interval τ at steady state (AUCτ,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Empaglifozin</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
    <description>apparent clearance of the analyte in plasma after first dose (CL/F) and at steady state (CL/F,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe0-24 of Empagliflozin</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
    <description>Fraction of analyte eliminated in urine from time point 0 to 24h after first dose (fe0-24) and at steady state (fe0-24,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LI (Linearity Index).</measure>
    <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 after drug administration on day 1 and 28</time_frame>
    <description>The linearity index is defined as AUC0-τ divided by AUC0-∞ both at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-24 of Glucose</measure>
    <time_frame>Day -2 and 27: -2 to 0, 0 to 5, 5 to 12 and 12 to 24h; Day -1 and 1: 0 to 5, 5 to 12 and 12 to 24; Day 28: 0 to 5, 5 to 12, 12 to 24, 24 to 36, 36 to 48 and 48 to 72h</time_frame>
    <description>Amount of glucose eliminated in urine over the time interval 0 to 24h on day -2, -1, 1, 27 and 28. (Urinary Glucose Excretion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG)</measure>
    <time_frame>in the morning of days -1 and 28</time_frame>
    <description>fasting plasma glucose on day -1 (baseline) and change from baseline to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Glucose (MDG) Measured in Blood</measure>
    <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00, 13:30, 24:00 h after drug administration on day -2. 0:05 h before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00, 13:30, 24:00 h after drug administration on day 1, 7, 14, 21 and 27</time_frame>
    <description>change from baseline in MDG on the days 1, 7, 14, 21 and 27. Baseline is defined as day -2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin AUEC0-5</measure>
    <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
    <description>change in AUEC0-5 from baseline on day 28. Baseline is defined as day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Emax (Maximum Measured Effect)</measure>
    <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
    <description>change in Emax from baseline on day 28. Baseline is defined as day -1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>in the morning of days -1( baseline), 1, 7, 14, 21 and 28</time_frame>
    <description>Change from baseline to the days 1, 7, 14, 21 and 28. Baseline is defined as day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Emax (Maximum Measured Effect)</measure>
    <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00, 24:00 h after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
    <description>Change from baseline (day -1) in Emax on day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon AUEC0-5</measure>
    <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
    <description>Change from baseline (day -1) in AUEC0-5 on day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>day -1 (baseline), 14 and 28</time_frame>
    <description>change from baseline to days 14 and 18. Baseline is defined as day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>in the morning of days -1 and 28</time_frame>
    <description>change from baseline on day 28. Baseline is defined as day -1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 low dose</intervention_name>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to BI 10773</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 medium dose</intervention_name>
    <arm_group_label>BI 10773 medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 high dose</intervention_name>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and postmenopausal or hysterectomised female patients with type 2 diabetes

          -  Age &gt;18 and &lt; 70 years

          -  BMI &gt;18.5 and &lt;40 kg/m2

        Exclusion Criteria:

          -  Antidiabetic treatment with insulin or glitazones or with more than one oral
             hypoglycaemic agent;

          -  Fasted blood glucose &gt; 240 mg/dl (&gt;13.3 mmol/L) or a blood glucose level above 400
             mg/dl (22.2 mmol/L) postprandially;

          -  HbA1c &gt; 8.5 %
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.4.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.4.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.4.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2007</study_first_submitted>
  <study_first_submitted_qc>November 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2007</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>July 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2014</results_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral administration in the fasted state once daily</description>
        </group>
        <group group_id="P2">
          <title>10mg Empagliflozin</title>
          <description>Oral administration in the fasted state once daily.</description>
        </group>
        <group group_id="P3">
          <title>25mg Empagliflozin</title>
          <description>Oral administration in the fasted state once daily.</description>
        </group>
        <group group_id="P4">
          <title>100mg Empagliflozin</title>
          <description>Oral administration in the fasted state once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>oral administration in the fasted state once daily.</description>
        </group>
        <group group_id="B2">
          <title>10mg Empagliflozin</title>
          <description>oral administration in the fasted state once daily.</description>
        </group>
        <group group_id="B3">
          <title>25mg Empagliflozin</title>
          <description>oral administration in the fasted state once daily.</description>
        </group>
        <group group_id="B4">
          <title>100mg Empagliflozin</title>
          <description>oral administration in the fasted state once daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="10.4"/>
                    <measurement group_id="B2" value="56.8" spread="8.7"/>
                    <measurement group_id="B3" value="56.1" spread="8.5"/>
                    <measurement group_id="B4" value="56.5" spread="8.2"/>
                    <measurement group_id="B5" value="56.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Drug Related Adverse Events</title>
        <description>number of subjects with investigator-defined drug-related adverse events.</description>
        <time_frame>from drug administration up to 6 weeks</time_frame>
        <population>treated set: comprised all 78 patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Drug Related Adverse Events</title>
          <description>number of subjects with investigator-defined drug-related adverse events.</description>
          <population>treated set: comprised all 78 patients who received at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
        <description>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>from drug administration up to 6 weeks</time_frame>
        <population>treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
          <description>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lipase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood triglycerides increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Empagliflozin</title>
        <description>maximum concentration of the analyte in plasma after first dose (Cmax, Day 1 ) and at steady state over a uniform dosing interval (Cmax,ss, Day 28).</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 hours(h) after drug administration on day 1 and 28</time_frame>
        <population>Pharmacokinetic (PK) analysis set: comprised all 62 patients who received Empagliflozin and had evaluable PK parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Empagliflozin</title>
          <description>maximum concentration of the analyte in plasma after first dose (Cmax, Day 1 ) and at steady state over a uniform dosing interval (Cmax,ss, Day 28).</description>
          <population>Pharmacokinetic (PK) analysis set: comprised all 62 patients who received Empagliflozin and had evaluable PK parameter data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309" spread="45.2"/>
                    <measurement group_id="O2" value="722" spread="20"/>
                    <measurement group_id="O3" value="2630" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" spread="24.8"/>
                    <measurement group_id="O2" value="687" spread="18.4"/>
                    <measurement group_id="O3" value="2390" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Empagliflozin</title>
        <description>time from last dosing to maximum concentration of the analyte in plasma after first dose (Day 1), denoted by tmax; and at steady state (Day 28), denoted by tmax,ss.</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Empagliflozin</title>
          <description>time from last dosing to maximum concentration of the analyte in plasma after first dose (Day 1), denoted by tmax; and at steady state (Day 28), denoted by tmax,ss.</description>
          <population>PK analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="29.8" lower_limit="1.00" upper_limit="2.50"/>
                    <measurement group_id="O2" value="1.50" spread="28.7" lower_limit="0.75" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.50" spread="30.9" lower_limit="0.75" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tmax,ss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="13" lower_limit="0.98" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.50" spread="14.9" lower_limit="0.75" upper_limit="3.02"/>
                    <measurement group_id="O3" value="1.50" spread="18.7" lower_limit="0.75" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 of Empagliflozin</title>
        <description>terminal half-life of the analyte in plasma after first dose (Day 1), denoted by t1/2; and at steady state (Day 28), denoted by t1/2,ss.</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Empagliflozin</title>
          <description>terminal half-life of the analyte in plasma after first dose (Day 1), denoted by t1/2; and at steady state (Day 28), denoted by t1/2,ss.</description>
          <population>PK analysis set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.69" spread="12.90"/>
                    <measurement group_id="O2" value="8.16" spread="14.50"/>
                    <measurement group_id="O3" value="8.53" spread="18.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1/2,ss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.20" spread="41.40"/>
                    <measurement group_id="O2" value="12.70" spread="32.70"/>
                    <measurement group_id="O3" value="15.00" spread="44.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ of Empagliflozin</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) and over a uniform dosing interval τ at steady state (AUCτ,ss)</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Empagliflozin</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) and over a uniform dosing interval τ at steady state (AUCτ,ss)</description>
          <population>PK analysis set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-∞</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1740" spread="16.4"/>
                    <measurement group_id="O2" value="4340" spread="23.1"/>
                    <measurement group_id="O3" value="18000" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCτ,ss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1870" spread="15.9"/>
                    <measurement group_id="O2" value="4740" spread="21.2"/>
                    <measurement group_id="O3" value="18700" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F of Empaglifozin</title>
        <description>apparent clearance of the analyte in plasma after first dose (CL/F) and at steady state (CL/F,ss)</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of Empaglifozin</title>
          <description>apparent clearance of the analyte in plasma after first dose (CL/F) and at steady state (CL/F,ss)</description>
          <population>PK analysis set</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL/F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" spread="15.3"/>
                    <measurement group_id="O2" value="223" spread="21.2"/>
                    <measurement group_id="O3" value="215" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL/F,ss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" spread="15.9"/>
                    <measurement group_id="O2" value="203" spread="21.4"/>
                    <measurement group_id="O3" value="208" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>fe0-24 of Empagliflozin</title>
        <description>Fraction of analyte eliminated in urine from time point 0 to 24h after first dose (fe0-24) and at steady state (fe0-24,ss)</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28</time_frame>
        <population>PK analysis set for patients who have fe data at day 1 and day 28</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>fe0-24 of Empagliflozin</title>
          <description>Fraction of analyte eliminated in urine from time point 0 to 24h after first dose (fe0-24) and at steady state (fe0-24,ss)</description>
          <population>PK analysis set for patients who have fe data at day 1 and day 28</population>
          <units>percentage of Empagliflozin</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fe0-24 (N=14,16,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="24"/>
                    <measurement group_id="O2" value="13.3" spread="24.5"/>
                    <measurement group_id="O3" value="13.7" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fe0-24,ss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="25"/>
                    <measurement group_id="O2" value="17.8" spread="17.8"/>
                    <measurement group_id="O3" value="17.5" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LI (Linearity Index).</title>
        <description>The linearity index is defined as AUC0-τ divided by AUC0-∞ both at steady state.</description>
        <time_frame>0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 after drug administration on day 1 and 28</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>LI (Linearity Index).</title>
          <description>The linearity index is defined as AUC0-τ divided by AUC0-∞ both at steady state.</description>
          <population>PK analysis set</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="11.1"/>
                    <measurement group_id="O2" value="1.1" spread="12.5"/>
                    <measurement group_id="O3" value="1.04" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-24 of Glucose</title>
        <description>Amount of glucose eliminated in urine over the time interval 0 to 24h on day -2, -1, 1, 27 and 28. (Urinary Glucose Excretion)</description>
        <time_frame>Day -2 and 27: -2 to 0, 0 to 5, 5 to 12 and 12 to 24h; Day -1 and 1: 0 to 5, 5 to 12 and 12 to 24; Day 28: 0 to 5, 5 to 12, 12 to 24, 24 to 36, 36 to 48 and 48 to 72h</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-24 of Glucose</title>
          <description>Amount of glucose eliminated in urine over the time interval 0 to 24h on day -2, -1, 1, 27 and 28. (Urinary Glucose Excretion)</description>
          <population>PD analysis set</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae0-24 on day -2 (N=15,16,15,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4270" spread="185"/>
                    <measurement group_id="O2" value="7760" spread="161"/>
                    <measurement group_id="O3" value="5340" spread="123"/>
                    <measurement group_id="O4" value="6050" spread="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-24 on day -1 (N=13,15,16,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6490" spread="136"/>
                    <measurement group_id="O2" value="8450" spread="114"/>
                    <measurement group_id="O3" value="8150" spread="91"/>
                    <measurement group_id="O4" value="6190" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-24 on day 1 (N=15,15,16,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3970" spread="197"/>
                    <measurement group_id="O2" value="81500" spread="35.7"/>
                    <measurement group_id="O3" value="95700" spread="30.4"/>
                    <measurement group_id="O4" value="87000" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-24 on day 27 (N=14,13,14,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3790" spread="296"/>
                    <measurement group_id="O2" value="78000" spread="44.1"/>
                    <measurement group_id="O3" value="82900" spread="32.9"/>
                    <measurement group_id="O4" value="81300" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-24 on day 28 (N=13,13,11,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6310" spread="230"/>
                    <measurement group_id="O2" value="75400" spread="44.6"/>
                    <measurement group_id="O3" value="83400" spread="26.4"/>
                    <measurement group_id="O4" value="73900" spread="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG)</title>
        <description>fasting plasma glucose on day -1 (baseline) and change from baseline to day 28</description>
        <time_frame>in the morning of days -1 and 28</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <description>fasting plasma glucose on day -1 (baseline) and change from baseline to day 28</description>
          <population>PD analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.87" spread="40.53"/>
                    <measurement group_id="O2" value="186.18" spread="92.96"/>
                    <measurement group_id="O3" value="167.49" spread="39.61"/>
                    <measurement group_id="O4" value="149.92" spread="31.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=15, 15, 16, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" spread="27.08"/>
                    <measurement group_id="O2" value="-43.7" spread="81.81"/>
                    <measurement group_id="O3" value="-34.22" spread="26.44"/>
                    <measurement group_id="O4" value="-28.69" spread="18.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Glucose (MDG) Measured in Blood</title>
        <description>change from baseline in MDG on the days 1, 7, 14, 21 and 27. Baseline is defined as day -2.</description>
        <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00, 13:30, 24:00 h after drug administration on day -2. 0:05 h before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00, 13:30, 24:00 h after drug administration on day 1, 7, 14, 21 and 27</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Glucose (MDG) Measured in Blood</title>
          <description>change from baseline in MDG on the days 1, 7, 14, 21 and 27. Baseline is defined as day -2.</description>
          <population>PD analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.06" spread="41.49"/>
                    <measurement group_id="O2" value="164.83" spread="43.18"/>
                    <measurement group_id="O3" value="166.26" spread="35.86"/>
                    <measurement group_id="O4" value="149.43" spread="34.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="18.37"/>
                    <measurement group_id="O2" value="-14.69" spread="15.81"/>
                    <measurement group_id="O3" value="-23.51" spread="17.26"/>
                    <measurement group_id="O4" value="-23.02" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="15.78"/>
                    <measurement group_id="O2" value="-25.45" spread="23.2"/>
                    <measurement group_id="O3" value="-28.58" spread="17.6"/>
                    <measurement group_id="O4" value="-21.17" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="28.05"/>
                    <measurement group_id="O2" value="-26.97" spread="27.9"/>
                    <measurement group_id="O3" value="-20.43" spread="24.69"/>
                    <measurement group_id="O4" value="-12.03" spread="28.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.41" spread="30.46"/>
                    <measurement group_id="O2" value="-26.47" spread="31.71"/>
                    <measurement group_id="O3" value="-19.68" spread="24.94"/>
                    <measurement group_id="O4" value="-13.93" spread="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.69" spread="32.01"/>
                    <measurement group_id="O2" value="-19.57" spread="28"/>
                    <measurement group_id="O3" value="-26.37" spread="18.74"/>
                    <measurement group_id="O4" value="-23.87" spread="18.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin AUEC0-5</title>
        <description>change in AUEC0-5 from baseline on day 28. Baseline is defined as day -1.</description>
        <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin AUEC0-5</title>
          <description>change in AUEC0-5 from baseline on day 28. Baseline is defined as day -1.</description>
          <population>PD analysis set</population>
          <units>µU*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.16" spread="70.85"/>
                    <measurement group_id="O2" value="117.34" spread="54.36"/>
                    <measurement group_id="O3" value="102.44" spread="65.8"/>
                    <measurement group_id="O4" value="121.53" spread="101.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=16, 16, 16, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.37" spread="99.44"/>
                    <measurement group_id="O2" value="3.24" spread="91.07"/>
                    <measurement group_id="O3" value="3.8" spread="73.66"/>
                    <measurement group_id="O4" value="8.83" spread="67.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Emax (Maximum Measured Effect)</title>
        <description>change in Emax from baseline on day 28. Baseline is defined as day -1</description>
        <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Emax (Maximum Measured Effect)</title>
          <description>change in Emax from baseline on day 28. Baseline is defined as day -1</description>
          <population>PD analysis set</population>
          <units>µU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.78" spread="28.35"/>
                    <measurement group_id="O2" value="48.09" spread="23.38"/>
                    <measurement group_id="O3" value="46.13" spread="24.7"/>
                    <measurement group_id="O4" value="53.06" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=16, 16, 16, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.77" spread="30.73"/>
                    <measurement group_id="O2" value="0.55" spread="36.94"/>
                    <measurement group_id="O3" value="-0.46" spread="28.46"/>
                    <measurement group_id="O4" value="2.92" spread="32.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin</title>
        <description>Change from baseline to the days 1, 7, 14, 21 and 28. Baseline is defined as day -1.</description>
        <time_frame>in the morning of days -1( baseline), 1, 7, 14, 21 and 28</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin</title>
          <description>Change from baseline to the days 1, 7, 14, 21 and 28. Baseline is defined as day -1.</description>
          <population>PD analysis set</population>
          <units>µU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1) (N=12,12,14,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="4.37"/>
                    <measurement group_id="O2" value="11.43" spread="6.23"/>
                    <measurement group_id="O3" value="8.74" spread="4.13"/>
                    <measurement group_id="O4" value="9.3" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 1 (N=11,12,14,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="2.9"/>
                    <measurement group_id="O2" value="-1.56" spread="3.97"/>
                    <measurement group_id="O3" value="-1.1" spread="2.29"/>
                    <measurement group_id="O4" value="0.15" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 7 (N=9,10,9,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="2.56"/>
                    <measurement group_id="O2" value="-2.49" spread="6.01"/>
                    <measurement group_id="O3" value="-1" spread="3.36"/>
                    <measurement group_id="O4" value="-0.2" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 14 (N=12,11,14,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="4.68"/>
                    <measurement group_id="O2" value="-1.16" spread="4.58"/>
                    <measurement group_id="O3" value="0.18" spread="2.74"/>
                    <measurement group_id="O4" value="1.37" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 21 (N=10,11,14,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="4.76"/>
                    <measurement group_id="O2" value="-0.17" spread="6.35"/>
                    <measurement group_id="O3" value="-1.21" spread="2.85"/>
                    <measurement group_id="O4" value="1.53" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=11,11,12,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.74"/>
                    <measurement group_id="O2" value="-2.89" spread="4.68"/>
                    <measurement group_id="O3" value="-1.73" spread="3.64"/>
                    <measurement group_id="O4" value="-2.1" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Emax (Maximum Measured Effect)</title>
        <description>Change from baseline (day -1) in Emax on day 28.</description>
        <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00, 24:00 h after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Emax (Maximum Measured Effect)</title>
          <description>Change from baseline (day -1) in Emax on day 28.</description>
          <population>PD analysis set</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.35" spread="18.01"/>
                    <measurement group_id="O2" value="90.58" spread="19.63"/>
                    <measurement group_id="O3" value="82.75" spread="17.79"/>
                    <measurement group_id="O4" value="86.98" spread="22.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=14, 14, 16, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.44" spread="28.69"/>
                    <measurement group_id="O2" value="13.69" spread="23.96"/>
                    <measurement group_id="O3" value="7.84" spread="16.66"/>
                    <measurement group_id="O4" value="6.84" spread="21.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon AUEC0-5</title>
        <description>Change from baseline (day -1) in AUEC0-5 on day 28.</description>
        <time_frame>0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.</time_frame>
        <population>Pharmacodynamic (PD) analysis set: All patients who receive at least one dose of study medication (active drug or placebo) and had some PD data were included in the pharmacodynamic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon AUEC0-5</title>
          <description>Change from baseline (day -1) in AUEC0-5 on day 28.</description>
          <population>Pharmacodynamic (PD) analysis set: All patients who receive at least one dose of study medication (active drug or placebo) and had some PD data were included in the pharmacodynamic analysis.</population>
          <units>ng*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.66" spread="74.99"/>
                    <measurement group_id="O2" value="310.76" spread="72.1"/>
                    <measurement group_id="O3" value="291.09" spread="104.11"/>
                    <measurement group_id="O4" value="303.06" spread="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=14, 14, 16, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" spread="81.1"/>
                    <measurement group_id="O2" value="59.69" spread="89.52"/>
                    <measurement group_id="O3" value="33.6" spread="73.09"/>
                    <measurement group_id="O4" value="40.65" spread="75.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fructosamine</title>
        <description>change from baseline to days 14 and 18. Baseline is defined as day -1.</description>
        <time_frame>day -1 (baseline), 14 and 28</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Fructosamine</title>
          <description>change from baseline to days 14 and 18. Baseline is defined as day -1.</description>
          <population>PD analysis set</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.27" spread="33.97"/>
                    <measurement group_id="O2" value="251.88" spread="39.19"/>
                    <measurement group_id="O3" value="257.88" spread="53.64"/>
                    <measurement group_id="O4" value="237.07" spread="41.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 14 (N=14, 16, 15, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.57" spread="24.67"/>
                    <measurement group_id="O2" value="24.75" spread="21.55"/>
                    <measurement group_id="O3" value="13.07" spread="20.83"/>
                    <measurement group_id="O4" value="18.31" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=14, 15, 16, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.57" spread="28.67"/>
                    <measurement group_id="O2" value="-24.33" spread="29.98"/>
                    <measurement group_id="O3" value="-22.06" spread="32.89"/>
                    <measurement group_id="O4" value="-26.29" spread="31.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c</title>
        <description>change from baseline on day 28. Baseline is defined as day -1.</description>
        <time_frame>in the morning of days -1 and 28</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration in the fasted state once daily</description>
          </group>
          <group group_id="O2">
            <title>10mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily</description>
          </group>
          <group group_id="O3">
            <title>25mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily</description>
          </group>
          <group group_id="O4">
            <title>100mg Empagliflozin</title>
            <description>Oral administration in the fasted state once daily</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <description>change from baseline on day 28. Baseline is defined as day -1.</description>
          <population>PD analysis set</population>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline (day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" spread="0.91"/>
                    <measurement group_id="O2" value="7.15" spread="0.67"/>
                    <measurement group_id="O3" value="7.45" spread="0.8"/>
                    <measurement group_id="O4" value="7.1" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to day 28 (N=13, 13, 15, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.62"/>
                    <measurement group_id="O2" value="-0.27" spread="0.36"/>
                    <measurement group_id="O3" value="-0.22" spread="0.32"/>
                    <measurement group_id="O4" value="-0.36" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening (35 to 15 days before treatment administration) until the end of study examination (35 to 41 days after treatment administration)</time_frame>
      <desc>Patients were required to report spontaneously any AEs, including the time of onset, duration and intensity of these events. Each patient could be assessed by the investigator whenever necessary.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>oral administration in the fasted state once daily</description>
        </group>
        <group group_id="E2">
          <title>10mg Empagliflozin</title>
          <description>oral administration in the fasted state once daily</description>
        </group>
        <group group_id="E3">
          <title>25mg Empagliflozin</title>
          <description>oral administration in the fasted state once daily</description>
        </group>
        <group group_id="E4">
          <title>100mg Empagliflozin</title>
          <description>oral administration in the fasted state once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

